Investor Relations

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing innovative products utilizing the FDA's 505(b)(2) regulatory pathway.

Eton has a diversified pipeline of product candidates under development across various liquid dosage forms, including injectables, oral liquids, and ophthalmics.

Volume :

Copyright West LLC. Minimum 15 minutes delayed.

News Releases
September 3, 2019
DEER PARK, Ill. , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen , Chief Executive Officer, will participate in the Lake Street
August 19, 2019
ET-104 Successfully Demonstrated Bioequivalence to Currently Approved Oral Solid Formulation New Drug Application (NDA) Submission Expected in Fourth Quarter of 2019 DEER PARK, Ill. --(BUSINESS WIRE)--Aug. 19, 2019-- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company
August 6, 2019
ET-203 NDA submitted, Three Additional Product Submissions Expected in 2019 ET-105 Acquisition Closed & Application Assigned PDUFA Date of March 17, 2020 Company to Host Conference Call and Webcast Today at 4:30p.m. ET ( 3:30 p.m. CT ) DEER PARK, Ill. , Aug.

Latest Event

Eton Pharma Reports Positive Top-Line Results from Phase III Trial of EM-100 Ophthalmic Solution
More events are coming soon.